Sangamo showcases Fabry progress at WORLDSymposium™

Translating groundbreaking science into tomorrow’s cures

Explore our science

Pioneering the future of genomic medicine

Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today’s medicine can only offer symptom management at best.

Explore our pipeline

Explore our latest corporate presentation by clicking below to stay informed and gain valuable insights into our company’s vision, achievements, and roadmap.

View the corporate presentation

The Latest at Sangamo


News


Priority Neurology Pipeline
Indication Technology Preclinical Phase 1/2 Pivotal
Chronic Neuropathic Pain (Nav1.7) ZF Genome Engineering
Prion Disease ZF Genome Engineering
Neurology (undisclosed) ZF Genome Engineering
Partnered Programs
Indication Technology Preclinical Phase 1/2 Pivotal
Hemophilia A (Giroctocogene fitelparvovec) Gene Therapy
Oncology Cell Therapy
ALS/FTD ZF Genome Engineering
Huntington’s Disease ZF Genome Engineering
Other Pipeline
Indication Technology Preclinical Phase 1/2 Pivotal
Fabry Disease Gene Therapy
Renal Transplant (TX200; Auto) Treg Cell Therapy
Inflammatory Bowel Disease Treg Cell Therapy
Multiple Sclerosis Treg Cell Therapy